BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 1954046)

  • 1. Mechanisms of osteolytic bone destruction.
    Mundy GR
    Bone; 1991; 12 Suppl 1():S1-6. PubMed ID: 1954046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bone hyperresorption in neoplastic diseases. Foreword].
    Vinceneux P
    Presse Med; 2000 Mar; 29(9):485-6. PubMed ID: 10745941
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pathophysiology of bone metastases in urologic carcinomas].
    Sauer G; Barth TF; Möller P
    Urologe A; 2007 Aug; 46(8):888-90. PubMed ID: 17632696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
    Chirgwin JM; Guise TA
    Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.
    Clines GA; Guise TA
    Endocr Relat Cancer; 2005 Sep; 12(3):549-83. PubMed ID: 16172192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of osteolytic bone metastases.
    Guise TA
    Cancer; 2000 Jun; 88(12 Suppl):2892-8. PubMed ID: 10898330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and the development of osteolytic metastases.
    de Vernejoul MC
    Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):119S-123S. PubMed ID: 9273953
    [No Abstract]   [Full Text] [Related]  

  • 8. Parathyroid hormone-related protein and bone metastases.
    Guise TA
    Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone hyperresorption in bone metastases].
    Clézardin P
    Presse Med; 2000 Mar; 29(9):487-91. PubMed ID: 10745942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer metastasis to bone: it is not all about PTHrP.
    Bendre M; Gaddy D; Nicholas RW; Suva LJ
    Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S39-45. PubMed ID: 14600591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor-beta in osteolytic breast cancer bone metastases.
    Guise TA; Chirgwin JM
    Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S32-8. PubMed ID: 14600590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parathyroid hormone-related protein in hypercalcemia associated with hematological malignancy.
    Firkin F; Schneider H; Grill V
    Leuk Lymphoma; 1998 May; 29(5-6):499-506. PubMed ID: 9643563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.
    Bataille R; Chappard D; Klein B
    Int J Clin Lab Res; 1992; 21(4):283-7. PubMed ID: 1591381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.
    Chantry AD; Heath D; Mulivor AW; Pearsall S; Baud'huin M; Coulton L; Evans H; Abdul N; Werner ED; Bouxsein ML; Key ML; Seehra J; Arnett TR; Vanderkerken K; Croucher P
    J Bone Miner Res; 2010 Dec; 25(12):2633-46. PubMed ID: 20533325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein.
    Wysolmerski JJ; Broadus AE
    Annu Rev Med; 1994; 45():189-200. PubMed ID: 8198376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone metastases and tumor-induced hypercalcemia.
    Body JJ
    Curr Opin Oncol; 1992 Aug; 4(4):624-31. PubMed ID: 1511019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of clodronate in multiple myeloma.
    Delmas PD
    Bone; 1991; 12 Suppl 1():S31-4. PubMed ID: 1835398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-bone cellular interactions in skeletal metastases.
    Chirgwin JM; Mohammad KS; Guise TA
    J Musculoskelet Neuronal Interact; 2004 Sep; 4(3):308-18. PubMed ID: 15615499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the use of bisphosphonates in bone metastases.
    Kanis JA; McCloskey EV; Taube T; O'Rourke N
    Bone; 1991; 12 Suppl 1():S13-8. PubMed ID: 1954047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.